Gene-edited porcine kidneys can provide sustained, life-supporting renal replacement in living human recipients with a clinically acceptable burden of rejection, infection and immunosuppression.
Evidence is materially increasing confidence in—or pressure on—the claim; significant uncertainty remains. State definitions
No evidence has been admitted since this assessment.
Retained questions may have been narrowed or reframed by the current assessment.
Verification position derived from the record’s assessments; dates show when Faultline first recorded each stage.
Editorial rendering for clarity; the assessment is unchanged.
Normal Record Review admits the peer-reviewed 271-day living-recipient xenokidney case as IN-008. The report materially strengthens the capability side of the claim: a gene-edited porcine kidney provided immediate function and sustained dialysis independence for nearly nine months, and subsequent human allotransplantation proceeded without detected xenograft-induced HLA sensitisation or porcine pathogen transmission. It also sharpens rather than removes the durability constraint. After immunosuppression was reduced during a bacterial infection, microvascular inflammation and endothelial injury progressed to thrombotic microangiopathy and graft failure, with macrophage- and natural-killer-cell-predominant infiltration. This directly reinforces RM-001 and the distinction between control of acute adaptive rejection and sustained xenogeneic immune/vascular compatibility. Pressure State remains ESCALATING and Verification Stage remains VS-03: durable living-human function is stronger than at admission, but the evidence remains an individual Expanded Access case and prospective multi-recipient replication has not yet been established.
Normal Record Review of the September 2026 Lancet candidate held outside LPR-001-D29. Source: Riella et al., The Lancet 408 (2026), 1029–1040, doi:10.1016/S0140-6736(26)01295-X. IN-003 remains as earlier chronology; IN-008 records the later peer-reviewed evidence and mechanistic detail.
Normal Record Review is the Observatory’s assessment process for newly considered evidence, not external scientific peer review. Expanded Access permits investigational treatment outside a clinical trial; a case treated this way is not itself a clinical trial or independent replication. LPR identifies an internal source-review record. PROG identifies a programme: AI (Artificial Intelligence), AM (Advanced Materials), BT (Biotechnology), or QE (Quantum Engineering).
How the claim could hold, what obstructs it, and possible ways forward. The State Warrant above remains the authoritative current assessment.
Multilayer xenogeneic immune control. Avoiding hyperacute rejection is insufficient; T-cell, antibody, complement, natural-killer-cell and monocyte/macrophage responses can still injure the graft. Durable clinical use requires these responses to be controlled without an immunosuppressive burden that negates the benefit of transplantation.
Persistent innate immune activation. Human immune profiling shows that adaptive rejection can be suppressed while monocyte and macrophage activation persists. This creates a plausible route to chronic inflammatory, vascular or fibrotic graft injury after an apparently successful treatment of acute rejection.
Cross-species renal physiology. Protein handling, haemodynamic regulation, complement and coagulation interactions, endocrine signalling and organ-growth biology differ between pigs and humans. These differences can produce progressive dysfunction even when immediate rejection is prevented.
Clinical reproducibility. Compassionate-use and individual living-recipient successes establish possibility but not a therapeutic modality. The claim requires prospectively repeated graft survival and renal function across multiple recipients, centres and donor-engineering strategies.
A recorded possible resolution path, not automatically a sufficient test for closing the claim.
Multigene donor engineering combined with targeted costimulation and complement control. Current programmes converge on removing major xenoantigens, adding human protective transgenes and using targeted immunosuppression. If prospective trials reproduce months-long function while reducing rejection and infection burden, this combination could convert xenokidneys from experimental rescue procedures into a scalable renal-replacement pathway.
Editorial rendering for clarity; the assessment is unchanged.
Normal Record Review admits the peer-reviewed 271-day living-recipient xenokidney case as IN-008. The report materially strengthens the capability side of the claim: a gene-edited porcine kidney provided immediate function and sustained dialysis independence for nearly nine months, and subsequent human allotransplantation proceeded without detected xenograft-induced HLA sensitisation or porcine pathogen transmission. It also sharpens rather than removes the durability constraint. After immunosuppression was reduced during a bacterial infection, microvascular inflammation and endothelial injury progressed to thrombotic microangiopathy and graft failure, with macrophage- and natural-killer-cell-predominant infiltration. This directly reinforces RM-001 and the distinction between control of acute adaptive rejection and sustained xenogeneic immune/vascular compatibility. Pressure State remains ESCALATING and Verification Stage remains VS-03: durable living-human function is stronger than at admission, but the evidence remains an individual Expanded Access case and prospective multi-recipient replication has not yet been established.
Normal Record Review of the September 2026 Lancet candidate held outside LPR-001-D29. Source: Riella et al., The Lancet 408 (2026), 1029–1040, doi:10.1016/S0140-6736(26)01295-X. IN-003 remains as earlier chronology; IN-008 records the later peer-reviewed evidence and mechanistic detail.
Historical narrative recorded for this claim. It does not override the current State Warrant.
Questions retained in this record. The current State Warrant may have narrowed or reframed them. Recorded dates refer to question history, not necessarily the age of the current wording; known revision dates are shown separately.
What duration and level of dialysis independence should constitute clinically meaningful durable renal replacement for this record?
Question recorded 2026-08-21Can persistent innate xenogeneic activation be sufficiently controlled without making the immunosuppressive burden clinically unacceptable?
Question recorded 2026-08-21Which long-term graft failures arise primarily from immune rejection and which arise from intrinsic cross-species renal physiology?
Question recorded 2026-08-21Do materially different donor-gene architectures converge on comparable human outcomes, or will durable xenokidney viability remain platform-dependent?
Question recorded 2026-08-21What prospective sample size and multicentre consistency should be required before the claim advances from VS-03 Audit to VS-04 Replication?
Question recorded 2026-08-21| Mutation | Date | Field | Prior value | Current value |
|---|---|---|---|---|
| M-011 | 2026-10-21 | Provenance review completedprovenance_review_completed | LPR-001-D29 | LPR-001-D57What this update recorded for M-011Second-cycle Legacy Provenance Review completed as PASS across all eight existing evidence instances. Underlying sources and claim representations verified; existing structured provenance is sufficient and no unverifiable attribution was introduced. No factual, interpretive, attribution or verification-stage discrepancy identified. A September 2026 report of another living recipient exceeding nine months with a functioning pig kidney was identified as genuinely new evidence and is held outside LPR-001 for Normal Record Review. Canonical outcome verified / not_required; Pressure State and Verification Stage unchanged. |
| M-010 | 2026-10-19 | Reference correctionreference_corrected | IN-004 recipient relationship implicit; IN-002 title says 51 days | IN-004 explicitly linked to IN-002 as same-recipient analysis; IN-002 title omits ambiguous durationWhat this update recorded for M-010Ribas et al., Nature Medicine, DOI 10.1038/s41591-025-04053-3, profiles the March 2024 first recipient reported by Kawai et al., NEJM, DOI 10.1056/NEJMoa2412747. Not another patient. Remove the unexplained 51-day title while preserving the description and source chronology documenting death on postoperative day 52. All assessments, sources, dates, vectors and historical mutations preserved; no new clinical evidence admitted. |
| M-009 | 2026-10-18 | Reference correctionreference_corrected | IN-003 / IN-008 relationship in narrative only | IN-008 explicitly linked to IN-003 as same-recipient follow-upWhat this update recorded for M-009Make the already recorded same-recipient relationship explicit and machine-readable. Preserve both entries, source chronology, descriptions, vectors and assessments. Eight logged entries do not mean eight independent cases. |
| M-008 | 2026-09-26 | Assessment issuedassessment_issued | AS-001 / ESCALATING / VS-03 | AS-002 / ESCALATING / VS-03What this update recorded for M-008Normal Record Review of the Lancet 271-day xenokidney case. Capability evidence strengthens and late microvascular/innate injury is better resolved, but prospective multi-recipient replication remains outstanding. |
| M-007 | 2026-09-26 | Instances loggedinstances_logged | IN-001–IN-007 | IN-001–IN-008What this update recorded for M-007Riella et al., Lancet 2026, admitted as IN-008 after being held outside LPR-001-D29. IN-003 retained as historical chronology rather than overwritten. |
| M-006 | 2026-09-26 | Provenance review completedprovenance_review_completed | — | LPR-001-D29What this update recorded for M-006Legacy provenance review completed. All seven existing instances verified against underlying or authoritative sources; structured sources[] added where attribution was confidently established. No factual, interpretive, attribution or verification-stage discrepancy identified. The September 2026 peer-reviewed Lancet report of the 271-day case was held outside LPR-001 as a Normal Record Review candidate. |
| M-005 | 2026-08-21 | Diagnosis helddiagnosis_held | — | DIAGNOSIS-HELDWhat this update recorded for M-005Admission diagnosis: ESCALATING / VS-03. Living-human renal replacement is demonstrated, while durability, rejection control and prospective reproducibility remain unresolved. |
| M-004 | 2026-08-21 | Mechanisms recordedmechanisms_recorded | — | MECHANISMS-RECORDEDWhat this update recorded for M-004BN-001, RM-001, RM-002, BN-002 and AT-001 recorded from the admission evidence package. |
| M-003 | 2026-08-21 | Assessment issuedassessment_issued | — | ASSESSMENT-ISSUEDWhat this update recorded for M-003AS-001 issued. Pressure State: ESCALATING. Verification Stage: VS-03. |
| M-002 | 2026-08-21 | Instances loggedinstances_logged | — | INSTANCES-LOGGEDWhat this update recorded for M-002IN-001 through IN-007 admitted as the initial two-sided evidence set. |
| M-001 | 2026-08-21 | Record createdrecord_created | — | RECORD-CREATEDWhat this update recorded for M-001FR-BT-0005 admitted following bounded PROG-BT coverage review and formal material-commitment reconstruction. |
Logged entries are reports on record, not counts of independent studies or patients. Several entries can concern the same underlying evidence. Supportive and Contesting describe an entry’s relation to the claim. Partial indicates limited or mixed bearing; read the details for limitations or legacy status. These labels are not study-quality ratings.
Early human decedent studies established that genetically modified porcine kidneys could reperfuse, produce urine and in some protocols normalize or substantially improve renal-function measures without immediate hyperacute rejection. These studies moved the claim beyond nonhuman-primate feasibility and exposed specific physiological and complement-mediated limitations, but they did not establish durable renal replacement in a living recipient.
Same recipient as IN-004; that entry reports immune profiling of this case, not an additional patient. View IN-004
A 62-year-old man with end-stage kidney disease received a 69-edit porcine kidney in March 2024. The graft provided essential renal functions including solute clearance, electrolyte homeostasis, urine concentration and blood-pressure regulation. A T-cell-mediated rejection episode occurred within the first week and was reversed with intensified immunosuppression. The recipient died from cardiac causes on day 52; autopsy found no evidence that graft rejection caused death. This is direct supportive evidence that a gene-edited porcine kidney can provide life-sustaining renal replacement in a living human for weeks, while also demonstrating that rejection control remains an active requirement.
Same recipient as IN-008; that entry is a later report of this case, not an independent patient. View IN-008
A subsequent living recipient maintained a gene-edited porcine kidney for 271 days before the graft was removed because of declining renal function and the patient returned to dialysis; the patient later received a human kidney transplant. This materially extends demonstrated durability from weeks to months, but it also shows that prolonged xenograft function does not yet equal durable clinical replacement. The case therefore exerts two-sided pressure on the claim.
Same recipient as IN-002: the first living-recipient transplant in March 2024. This paper profiles that recipient’s immune response; it is not an additional patient. View IN-002
High-dimensional profiling of the first living-recipient xenokidney showed early T-cell-mediated rejection despite profound circulating T-cell depletion. Intensified immunosuppression reversed the adaptive rejection episode, but sustained monocyte and macrophage activity and elevated inflammatory signalling persisted. The rejection profile shared features with human kidney allograft rejection while also showing distinct innate signatures. This directly identifies persistent innate immune activation as a biological resistance mechanism that may limit durability even when acute adaptive rejection is controlled.
United Therapeutics' EXPAND study is a prospective multicentre interventional trial of a 10-gene-edited porcine kidney in patients with end-stage renal disease. The study began in 2025, has an estimated enrollment of 50 participants, and evaluates participant survival, graft survival and function, glomerular filtration rate, quality of life, rejection, proteinuria and infectious complications at 24 weeks, followed by long-term surveillance. The first transplant in the study was announced in November 2025. This does not itself prove efficacy, but it creates a governed prospective replication pathway for the class-level claim.
Contemporary clinical review of living-recipient and decedent xenokidney experience finds that avoidance of hyperacute rejection does not eliminate early humoral activation, antibody-mediated injury, complement-dependent injury, proteinuria and other physiological incompatibilities. Reported cases include treatable rejection as well as graft dysfunction and infection-driven reductions in immunosuppression. This supports the view that the frontier has shifted from immediate compatibility to sustained immune and physiological control.
FDA xenotransplantation guidance requires sponsors using porcine xenotransplantation products to maintain plans for detection, confirmation and response to porcine endogenous retroviruses and other xenogeneic infectious agents, including recipient follow-up and public-health contingency planning. No clinical PERV transmission signal is established here; the evidence instead shows that infectious risk remains an explicit long-horizon condition of routine clinical deployment.
Same recipient as IN-003. This is the later peer-reviewed report of the 271-day case, not another patient or independent replication. View IN-003
Riella et al. report in The Lancet the first recipient in a planned three-patient FDA Expanded Access study using the 69-edit EGEN-2784 porcine kidney. The xenograft functioned immediately and sustained dialysis independence for 271 days. An early T-cell-mediated rejection episode resolved with treatment. After approximately six months of stable function, immunosuppression was reduced during a non-zoonotic bacterial infection; microvascular inflammation and endothelial injury subsequently progressed to thrombotic microangiopathy and graft failure, with macrophage- and natural-killer-cell-predominant infiltration and minimal T-cell involvement. No porcine pathogen transmission was detected and anti-HLA antibodies remained unchanged. Eighty-two days after xenograft explantation, the recipient received a human kidney with immediate graft function and no evidence of sensitisation during 231 days of follow-up. The case therefore strengthens evidence for months-long life-supporting renal replacement and demonstrates feasibility as a bridge to allotransplantation, while directly exposing late microvascular and innate-immune injury as a durability barrier.